Celgene Corp (CELG) 88.34 $CELG
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Final Glance: Biotechnology companies
AP - Wed Jul 30, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Midday Glance: Biotechnology companies
AP - Wed Jul 30, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 12:10PM CDT
Vertex Pharma (VRTX) posted a wider second quarter loss and also missed revenue expectations.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Early Glance: Biotechnology companies
AP - Wed Jul 30, 9:42AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Celgene (CELG) Breaks Through Resistance at $88.45
Comtex SmarTrend(R) - Wed Jul 30, 9:30AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $87.80 today and has reached the first level of resistance at $88.45. Should the shares continue to rise, the resistance pivots of $89.17 and $90.54 will be of interest.
Amgen Beats on Q2 Earnings & Revs, Ups View & Plans Job Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 8:20AM CDT
While Amgen's (AMGN) second quarter results were impressive, the company's restructuring plan remained in focus.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Why Celgene Stock Was Down 3% Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:05PM CDT
Celgene turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today). In...
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Final Glance: Biotechnology companies
AP - Wed Jul 30, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Midday Glance: Biotechnology companies
AP - Wed Jul 30, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 12:10PM CDT
Vertex Pharma (VRTX) posted a wider second quarter loss and also missed revenue expectations.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Early Glance: Biotechnology companies
AP - Wed Jul 30, 9:42AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Celgene (CELG) Breaks Through Resistance at $88.45
Comtex SmarTrend(R) - Wed Jul 30, 9:30AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $87.80 today and has reached the first level of resistance at $88.45. Should the shares continue to rise, the resistance pivots of $89.17 and $90.54 will be of interest.
Amgen Beats on Q2 Earnings & Revs, Ups View & Plans Job Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 8:20AM CDT
While Amgen's (AMGN) second quarter results were impressive, the company's restructuring plan remained in focus.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Why Celgene Stock Was Down 3% Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:05PM CDT
Celgene turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today). In...
